Our history

Ibi’s history is made up of a past rich in satisfaction, work, entrepreneurship and know-how, animated by people, ideas, creativity, visionary strategy, the desire for continuous improvement in research and the determination to face challenges. Ibi is all this and more, a piece of history and an Italian reality.

Istituto Biochimico Italiano  Giovanni Lorenzini S.p.a. (Ibi), a historical company on the Italian pharmaceutical scene, was founded in Milan in 1918 by Prof. Giovanni Lorenzini. Under his guidance Ibi specialized in research and pharmaceutical production, especially in the field of vitamins. In the early years of research into these substances, Ibi was groundbreaking in its research in extraction methods, dosage, and the stabilization of vitamins which had just been discovered. The company developed the first multivitamin for therapeutic use, the well known Lorenzini Vitamin.

Prof. Lorenzini’s desire to offer a service to society gave birth to the company’s mission “To make - To give”. Ibi has been pursuing this mission since its foundation as witnessed by its vital role in society during both World Wars as a supplier of the nation’s need for ascorbic acid, thiamin and insulin.

Ever since 1940 Ibi has been under female management. On the death of its founder, his daughter Loredana Lorenzini took over the management of the company and focussed attention on the development of the field of ethical specialities for the Italian market and to export of both finished and bulk products throughout the world. From 1956 on, Ibi concentrated on research into antibiotics. The company has developed more efficient production methods for new semi-synthetic antibiotic derivates that guarantee their quality.

In 1961 Ibi was one of the first Italian companies to receive FDA certification to export ß-lactam and oral antibiotics to the USA, a fact that testifies to the high level of quality reached. In the seventies the company proceeded to a phase of roll out of it’s know how, building important facilities for the production of antibiotics abroad (in Algeria, Cuba, Nigeria, Egypt and Panama). The enlargement of the head office in the centre of Milan became necessary and the Aprilia factory, now the company head office, was inaugurated. The leadership of Loredana Lorenzini, a strong, determined woman, enabled the company to become one of the first pharmaceutical companies on the Italian scene in the 80ies.

1990 was a year of transition for Ibi. Loredana Lorenzini was succeeded by her  granddaughter, Camilla Borghese Khevenhuller the present President and Managing Director of the company. About 70 years after its foundation Ibi found itself in the position of having to face profound changes on the Italian Pharmaceutical market. In order to rationalize resources the company concentrated both production (in the nineties) and the head office (in 2003) in Aprilia.
A renewal of the management has given a new boost to the development of the company, consolidating and expanding it on both the national and international markets. As a result, Ibi has become a well known brand throughout the world, as an exporter both of raw materials and finished products.

In 2004 Ibi became a key supplier for important companies in the UK, USA, Germany and Australia. The growth of exports to foreign markets and the consequent need for increased production led to the inauguration of a new building entirely dedicated to the production of ß-lactam in 2007.

In 2006 recognized the need to adapt its organization to a European dimension and react to the rise of companies specialized in generic drugs. In collaboration with a well known European group, the company founded Ibisqus, specialized in the area of hospital sales, in the UK, Italy and Germany.

Today more than ever Ibi is following its vocation, continuing to play a modern, creative role on the national pharmaceutical scene. In the face of a continuously changing market reality, Ibi continues to react, adopting new innovative technologies and strategies. A desire for innovation and development, have led the company to become involved in the increasingly recognized world of nanomedicine. An increasingly specialized know how and state of the art laboratories enable Ibi to face new challenges and to offer products and services in line with the mission of its founder “To make - To give” and its aim of improving quality of life.